Plain-English translation of NCT06933134 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial tests whether doctors can use blood tests to predict how well patients with rheumatoid arthritis will respond to a lower dose of rituximab. You would continue taking this medication at a reduced dose while the research team measures specific markers in your blood — like immune cell counts and drug levels — to see if they can reliably predict whether the lower dose will work for you.
Rituximab is very effective for rheumatoid arthritis, but higher doses can increase the risk of infections and other side effects. Doctors want to find the lowest dose that still works well for each patient, but right now they don't have a reliable way to predict who can safely switch to a lower dose — so this study is testing whether blood tests can guide that decision.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic every 3 months for 12 months. At your first visit, you would receive your first dose of lower-dose medication, and at 6 months you would receive a second dose. At each visit, the team would draw blood to measure immune cells, drug levels, and other markers, and they would check how well your arthritis is controlled using standard assessment tools. The study is observational, meaning you are not being asked to change your normal care — just to allow careful monitoring and blood testing.
AI-generated summary from trial data · Jun 23, 2026 · Not medical advice
France
University Hospital, Tours
Enrollment target
~30 participants
Started
April 2026
Primary completion
November 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in April 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Simon BRUNET
University Hospital, Tours
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.